首页 | 本学科首页   官方微博 | 高级检索  
     


A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study
Authors:Noritomo Shimada  Akihito Tsubota  Masanori Atsukawa  Hiroshi Abe  Tatsuya Ide  Koichi Takaguchi  Yoshimichi Chuganji  Hidenori Toyoda  Kai Yoshizawa  Makiko Ika  Yoshiyuki Sato  Keizo Kato  Takashi Kumada  Choitsu Sakamoto  Yoshio Aizawa  Michio Sata
Affiliation:1. Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, , Matsudo, Japan;2. Institute of Clinical Medicine and Research, Jikei University School of Medicine, , Kashiwa, Japan;3. Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, , Chiba, Japan;4. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, , Tokyo, Japan;5. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, , Kurume, Japan;6. Department of Hepatology, Kagawa Prefectural Central Hospital, , Takamatsu, Japan;7. Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, , Tokyo, Japan;8. Department of Gastroenterology, Ogaki Municipal Hospital, , Ogaki, Japan;9. Department of Gastroenterology, Machida Municipal Hospital, , Tokyo, Japan;10. Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School, , Tokyo, Japan
Abstract:
Keywords:48‐week therapy  chronic hepatitis C  non‐responders  telaprevir
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号